Physicians' Academy for Cardiovascular Education

Managing blood pressure: The need for individualized treatment considerations to reach targets

3' education - Dec. 6, 2011

Prof. Richard Hobbs emphasized the need for individualized considerations to reach treatment targets. In his view, the present interest largely relates to the potential for gene research. “Obviously that is a way off.” However, the health systems are dominated by the most cost-effective approach: an economically-driven population model, which tends to swamp the individual considerations.
For example, in the case of hypertension, the age of a patient might determine treatment decisions. Other phenotypes, like diabetes or other comorbidities, also ought to influence the treatment choice.

He thinks the current NICE guidelines only really encourage an individual approach in this very first age-related choice of agents. “We will see a lot more experimentation around personalized treatment options and probably guidance will continue to be refined on the basis of those studies.”

Topics discussed in this PACE talk:

  • What is your advise for individualized medicine to reduce CV risk?
  • Do the NICE guidelines provide sufficient foundation to be able to practice individualized medicine?

About the speaker:
Richard Hobbs is currently Professor and Head of the Department of Primary Health Care at the University of Oxford. He is the Director of the NIHR National School for Primary Care Research (2009-) and was co-Director of the Quality and Outcomes (QOF) Review Panel from 2005-09. He sits on several national and international scientific and research funding boards, including the Council of the British Heart Foundation and the Board of the British Primary Care Cardiovascular Society. He currently Chairs the Council for Cardiovascular Primary Care, European Society of Cardiology (ESC); the Prevention and Care Board, British Heart Foundation; and the European Primary Care Cardiovascular Society (EPCCS).
Professor Hobbs‘ research interests focus on cardiovascular epidemiology and clinical trials, especially relating to vascular and stroke risk, and heart failure. Overall his publications include 28 book chapters, 12 edited books and over 320 original papers in peer reviewed journals such as the Lancet, Annals of Internal Medicine, BMJ, Atherosclerosis, EHJ and Stroke. His research has impacted on international health policies and clinical guidelines. Within the NHS, he has consulted on National Service Frameworks for CHD, atrial fibrillation, and heart failure and several National Institute of Clinical Excellence (NICE) reviews. He has provided clinical care in inner-city general practice for 30 years.

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: